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Abstract
Osteoporosis is associated with an increased risk for atypical fractures (Dunphy, WinlandBrown, Porter & Thomas, 2015). It is a disease affecting eight-million women and two-million
men in the United States of America. This disease is largely associated with advanced age,
female gender and other comorbidities, and proper treatment is essential. Multiple treatment
modalities are available, both pharmacologic and non-pharmacologic (Lindsay & Cosman,
2018). Recommendations for prevention of osteoporotic fracture are prevalent, but
recommendations regarding pharmacologic treatment in the post-operative period is lacking. One
pharmacologic treatment, Bisphosphonate (BP) therapy, remains controversial; as evidence
regarding safety for patients in the post-operative recovery period is minimal (Cho et al., 2015).
The following is a case analysis with a thorough literature review highlighting the risks and
benefits of administering BP therapy to osteoporotic patients in the post-operative period.
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Risks and Benefits of Administering Bisphosphonates with a
Diagnosis of Atypical Osteoporotic Fracture
Background
Osteoporosis
Osteoporosis is a reduction in bone strength that leads to deterioration of human skeletal
framework and is associated with an increased risk for fractures (Dunphy, Winland-Brown,
Porter & Thomas, 2015). A clinical diagnosis of osteoporosis is identified by a bone mineral
density (BMD) of 2.5 standard deviations (SD) below the mean for healthy adults; the BMD is
measured radiographically via the dual energy x-ray absorptiometry (DXA) scan in the lumbar
spine, total hip or femoral neck, and is also known as the T-score (Lindsay & Cosman, 2018).
The development of osteoporosis is largely based on nonmodifiable and potentially
modifiable risk factors. Nonmodifiable risk factors include female gender, advanced age,
Caucasian race, genetics, comorbid dementia and personal history of fracture as an adult.
Potentially modifiable risk factors include tobacco use, a history of glucocorticoid use, estrogen
deficiency, inadequate nutrition hindering calcium and vitamin D intake, alcoholism, falls and
inadequate physical activity (Lindsay & Cosman, 2018).
With osteoporosis comes an increased risk for atypical osteoporotic fractures, which
often require surgical intervention for repair. The practitioner’s goal for treatment of patients
with osteoporosis is to prevent and manage acute fractures, while treating the underlying disease
process. The first step in treating osteoporosis is to reduce the impact of modifiable risk factors
such as those listed previously in this paper. Lifestyle changes regarding nutrition intake and
physical activity are typically involved in the plan of care. Pharmacologic interventions are also
utilized; these include Vitamin D and Calcium supplementation, Selective Estrogen Receptor
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Modulators (SERMs), hormone replacement therapy (HRT) and bisphosphonates (BP). These
medications are Food and Drug Administration (FDA) approved for the prevention and treatment
of osteoporosis (Lindsay & Cosman, 2018).
Bone Remodeling
This paper is largely focused on the effects of BP activity on bone recovery.
Understanding the mechanism of action of BP therapy requires knowing how the human body
performs bone-turnover or remodeling following a fracture. Bone remodeling involves the
combined activity of cells called osteoclasts and osteoblasts. Osteoclasts are multinucleated cells
that remove damaged bone and resorb calcified bone matrix during bone remodeling. Osteoblasts
are cells that secreted organic components into the bony matrix to synthesize the formation of
bone (Mescher, 2018). Effective bone remodeling requires continuous resorption of bone tissue
equal to the amount of new bone being laid down at a given site. Following the fracture of a
bone, blood vessels form a clot around the site which is eventually replaced by a hard callus
created by osteoblasts. Eventually the callus is invaded by the vasculature, allowing osteoclasts
to enter the area to resorb the hard callus into woven bone. A secondary remodeling phase
follows, which includes more resorption by osteoclasts, remodeling of the original fractured bone
below the callus, and formation of laminar bone via osteoblasts. (Lindsay & Cosman, 2018;
Kates & Ackert-Bicknell, 2016).
Bisphosphonates work to combat osteoporosis by directly impairing osteoclast resorption
function. They also work to reduce the presence of osteoclasts in the human body by apoptosis
(Lindsay & Cosman, 2018). Use of BP therapy is controversial because of the potential
theoretical risk of suppression of bone turnover and impairment of bone remodeling (Koh,
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Guerado, & Giannoudis, 2017). In theory, the use of BP could interfere with fracture healing in
patients with osteoporosis due to decrease osteoclast function (Cho et al., 2015).
Purpose
The purpose of this paper is to identify what risks or benefits, if any, there are in
administering BP therapy to patients with a clinical diagnosis of atypical osteoporotic fracture
requiring surgical intervention. Accompanying a thorough literature review is a case study
involving a seventy-two-year-old woman, with a recent diagnosis of atypical femoral fracture,
who presents to the clinic following surgical repair.
Case Report
A seventy-two-year-old female presents to the outpatient clinic for a follow-up
evaluation. She was recently discharged from the hospital after a three-day-stay after an open
reduction and internal fixation (ORIF) of her right hip, originating from an at-home fall. Her past
medical history includes Chronic Obstructive Pulmonary Disorder (COPD), Anemia,
Hypertension, Hypercholesterolemia and tobacco use, one pack per day for forty-five years. Her
current medications include Fluticasone-propionate and salmeterol, Metoprolol, Quetiapine and
Iron sulfate, twice a day, and Losartan, Paroxetine, Lipitor and a multivitamin, daily. Most
recently she completed a Prednisone taper following an acute COPD exacerbation. A thorough
social history reveals she is widowed, lives alone, follows a dairy-free diet, and performs daily
home exercises she learned at physical therapy, of which she completed a week ago.
Review of her symptoms finds she is “feeling more tired than usual”, is experiencing a
new-onset poor appetite, and occasional pain in her right hip, rated a 3/10, occurring before bed,
described as aching, exacerbated by overuse and relieved by acetaminophen and rest. Physical
examination reveals a normal exam, with full range of motion, good strength, balance and
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reflexes in bilateral lower extremities. Visualization of her surgical incision shows a wellhealing, approximated incision, negative for swelling, drainage, erythema or pain with palpation.
Assessment of the patient’s risks for fracture including age, post-menopausal state,
chronic tobacco use, dairy-free diet and history of glucocorticoid use prompted further
evaluation to determine the etiology of her right hip fracture. A dual energy x-ray
absorptiometry (DXA) scan was ordered to assess her bone mineral density and the results of the
scan are were a T-score of -2.6, which is diagnostic of osteoporosis. Her agreed-upon treatment
plan included supplemental administration of Calcium, 1,200 mg, and vitamin D, 800
international units daily and incorporating a daily oral bisphosphonate, while continuing at-home
exercises and joining her local Silver Sneakers program. Follow-up evaluation of her physiologic
response to her treatment included a plan to reassess her bone mineral density with a repeat DXA
scan in two years.
Literature review
In conducting a literature review, articles were reviewed using the Cumulative Index of
Nursing and Allied Health Literature (CINAHL), MEDLINE Complete, Pubmed and Pubmed
Central (PMC) databases. Limitations applied to the search included available articles published
within five years (2014-2019), pertaining to the adult population, of whom experienced an
atypical osteoporotic long-bone fracture, was treated with surgical repair and received
bisphosphonates in the pre- or post-operative periods. These criteria revealed a narrow amount of
information, so the search was expanded to include surgical repair of osteoporotic joints, which
yielded outcomes of bisphosphonate use with osteoporotic knee and hip arthroplasties; a total of
eleven articles were utilized in this review.
Summary of Findings
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Utilizing the Oxford Centre for Evidence-Based Medicine (CEBM) Levels of Evidence
(2011), eleven articles were evaluated, and the findings summarized. The levels are evidence are
rated from level 1 to 5: level 1 evidence is systematic reviews of randomized control trials
(RCT), individual RCT and meta-analyses. Level 2 evidence is from systematic reviews of
cohort studies and individual cohort studies, level 3 evidence stems from review of case-control
studies and individual case-control studies, level 4 evidence includes case series, case control
and poor-quality cohorts, and finally, level 5 evidence includes expert opinions, experimental
research and animal studies. The level of evidence is most credible with a level 1 rating (Howick
et al., 2011).
Level 1 evidence from a meta-analysis of 2,500 patients with differing osteoporotic
fractures found that anti-osteoporotic medications such as BPs, which possess antiresorptive
activity, showed no clinically significant delay in fracture healing and are safe to be given in the
pre- and post-operative period to reduce the incidence of future fractures (Bartl, Stengel, Gulke,
& Gebhard, 2016). Li, Cai & Zhang (2015) formed a meta-analysis evaluating for a delay in
healing based on clinical and radiologic findings and bone-turnover markers. This is another
example of level 1 evidence that patients treated with BP therapy less than three months postoperatively had no significant differences in healing time when compared to non-BP-users.
Recommendation was made for BP therapy to be started immediately following surgical repair
as there was also level 1 evidence this would prevent subsequent fractures. (Li et al., 2015).
Ng, Yue, Joseph & Richardson (2014) found level 2 evidence found stating that initiating
BP therapy at different times following an atypical osteoporotic fracture showed no difference in
healing time. The benefit of BP therapy for prevention of future fractures in such patients
outweighs risk of non-union (Ng, Yue, Joseph & Richardson, 2014). Kates & Ackert-Bicknell

RISKS AND BENEFITS OF ADMINISTERING BISPHOSPHONATES

9

(2016) also found level 2 evidence of no delay in bone-union with initiation of BPs immediately
after diagnosis of an atypical osteoporotic long-bone fracture. Patients already on long-term BP
therapy had a delay in bone-union 26% of the time, however, insufficient data prevented the
analysis from being fully understood (Kates & Ackert-Bicknell, 2016). Xue Li, Chen, Yan & Pan
(2014) evaluated the treatment of patients with BPs during bone healing and level 1 evidence
showed there is no association with BP use, delay in direct bone healing or fracture nonunion.
Also, delaying the administration of BPs following a confirmed atypical osteoporotic fracture
had no effect on bone healing. Finally, this meta-analysis confirmed recommendations that
treatment BPs should be done after the first osteoporotic fracture to increase bone mineral
density and reduce the risk of future fractures (Xue et al., 2014).
A case-control study compared outcomes of bisphosphonate naïve patients who were
administered BPs any time during a twenty-four-month post-operative period with BP naïve
patients who were non-users of these drugs. The rate of new clinical fracture was found to be
increased in BP users during the first six months of treatment, the difference eventually
decreasing over time, and by month eighteen, the rate of fracture was similar for both cohorts.
Level 3 evidence was used to support administering BPs as beneficial to the patient upon clinical
diagnosis of an atypical osteoporotic fracture (Bergman, Nordström & Nordström 2018).
Alternatively, Prieto-Alhambra et al. (2014) found level 3 evidence suggesting osteoporotic
patients who received total knee or hip arthroplasties and became BP users for at least six months
in the post-operative period had a fifty-nine percent reduced risk for surgical revision (PrietoAlhambra et al., 2014).
Level 3 evidence states there is no statistical evidence to support delayed or non-healing
bone following repair of an osteoporotic fracture. Recommendation was made for patients who
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have taken BPs for five years or more, that they may have an increased risk for a decrease in
bone formation and remodeling, therefore requiring surgery to be performed by experienced
surgeons. Further, a suggestion was made for patients to have a ‘drug holiday’ after five years of
BP therapy to prevent such complications (Phillips, Harrison, Akrawi & Sidhom, 2017). These
findings are somewhat contradictory to Koh, Guerado & Giannoudis (2017) who found level 2
evidence of no significant different in length of healing time in comparing patients taking BPs
for less than five years versus patients taking BPs greater than five years. It also suggests there is
no clinically significant risk of revisional surgery in either of these patient groups (Koh, Guerado
& Giannoudis, 2017).
In comparing patients with osteoporotic intertrochanteric fractures who received BP
therapy at either one week, one month or three months following surgical repair, the time of bone
union, as evidenced by radiographic callus formation, there was no significant difference in bone
union. This confirmed level 2 evidence that delaying initiation of BPs in the post-operative
period does not affect the length of healing time. Subsequently, early administration of BPs was
found to prevent future osteoporotic fractures (Cho et al., 2015).
Finally, a study comparing osteoporotic patients with atypical fractures of the proximal
humerus were evaluated for length of time for radiographic bone-union when receiving BP
therapy starting at either two weeks or three months into the post-operative period. Level 2
evidence found that delaying BP treatment does not significantly affect healing outcomes in
these patients (Seo, Yoo, Ryu & Yu, 2016).
Recommendations for Practice
•

Use of bisphosphonates in the post-operative period does not increase healing time or
prevent bone-union in surgically repaired atypical osteoporotic fractures.
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Delaying administration of bisphosphonates is not beneficial in patients with a confirmed
clinical diagnosis of atypical osteoporotic fracture, who are having surgical repair.

•

Administering bisphosphonates to patients with a confirmed clinical diagnosis of atypical
osteoporotic fracture is beneficial in preventing future fractures.
Conclusion
Osteoporosis remains a major health concern among post-menopausal women and at this

time, BP therapy is the most widely used treatment for it (Li et al., 2015). With thoughtful
consideration of information found in the thorough literature review, recommendations for
practice can be made for administration of BP’s with a concurrent diagnosis of atypical
osteoporotic fracture as it relates the case presented. Although there was a variety of level one
evidence regarding the benefit of BP’s immediately upon diagnosis, the risk of impaired bone
healing is still somewhat unknown. Until stronger research is presented regarding impaired bone
healing, the benefit of anti-osteoclastic activity associated with BP use outweighs hypothesized
risk.
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